La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Rhinomed Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Michael Johnson

Directeur général

AU$531.6k

Rémunération totale

Pourcentage du salaire du PDG	69.8%
Durée du mandat du directeur général	11yrs
Propriété du PDG	0.6%
Durée moyenne d'occupation des postes de direction	pas de données
Durée moyenne du mandat des membres du conseil d'administration	5.5yrs

Mises à jour récentes de la gestion

Recent updates

Analyse de la rémunération des PDG

Comment la rémunération de Michael Johnson a-t-elle évolué par rapport aux bénéfices de Rhinomed?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2023	AU$532k	AU$371k	-AU$11m
Mar 31 2023	n/a	n/a	-AU$9m
Dec 31 2022	n/a	n/a	-AU$7m
Sep 30 2022	n/a	n/a	-AU$6m
Jun 30 2022	AU$369k	AU$301k	-AU$5m
Mar 31 2022	n/a	n/a	-AU$6m
Dec 31 2021	n/a	n/a	-AU$6m
Sep 30 2021	n/a	n/a	-AU$8m
Jun 30 2021	AU$2m	AU$304k	-AU$9m
Mar 31 2021	n/a	n/a	-AU$8m
Dec 31 2020	n/a	n/a	-AU$7m
Sep 30 2020	n/a	n/a	-AU$7m
Jun 30 2020	AU$1m	AU$304k	-AU$7m
Mar 31 2020	n/a	n/a	-AU$8m
Dec 31 2019	n/a	n/a	-AU$8m
Sep 30 2019	n/a	n/a	-AU$7m
Jun 30 2019	AU$748k	AU$305k	-AU$6m
Mar 31 2019	n/a	n/a	-AU$5m
Dec 31 2018	n/a	n/a	-AU$5m
Sep 30 2018	n/a	n/a	-AU$5m
Jun 30 2018	AU$363k	AU$255k	-AU$4m
Mar 31 2018	n/a	n/a	-AU$4m
Dec 31 2017	n/a	n/a	-AU$5m
Sep 30 2017	n/a	n/a	-AU$5m
Jun 30 2017	AU$672k	AU$231k	-AU$4m

Rémunération vs marché: La rémunération totale de Michael ($USD 347.11K ) est dans la moyenne des entreprises de taille similaire sur le marché Australian ($USD 299.11K ).

Rémunération et revenus: La rémunération de Michael a augmenté alors que l'entreprise n'est pas rentable.

PDG

Michael Johnson

11yrs

Titularisation

AU$531,600

Compensation

Mr. Michael Johnson serves as the Chief Executive Officer, Managing Director and Executive Director of Rhinomed Limited (formerly, Consegna Group Limited) since February 1, 2013. Mr. Johnson serves as a Di...

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Michael Johnson	CEO, MD & Executive Director	11yrs	AU$531.60k	0.64% A$ 73.9k
Ross MacDonald	Member of the Medical Advisory Board	no data	pas de données	pas de données
Ronald Dewhurst	Independent Non-Executive Chairman	8.2yrs	AU$110.00k	6.88% A$ 792.3k
Steve Harris	Member of the Medical Advisory Board	no data	pas de données	pas de données
Lynette Swinburne	Non-Executive Director	1.4yrs	AU$58.45k	0.062% A$ 7.1k
John McBain	Non-Executive Director	2.8yrs	AU$73.33k	18.43% A$ 2.1m

5.5yrs

Durée moyenne de l'emploi

Conseil d'administration expérimenté: Les membres du conseil d'administration de RNO sont considérés comme expérimentés (ancienneté moyenne 5.5 ans).

Rhinomed Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Less than half of directors are independent

Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director

Less than half of directors are independent

Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023

Less than half of directors are independent

Rhinomed Limited, Annual General Meeting, Nov 17, 2023

Recent updates

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Rhinomed Limited has filed a Follow-on Equity Offering in the amount of AUD 1.25 million.

Less than half of directors are independent

Rhinomed Limited Withdraws the Resolution for Re-Election of Ryan McIntyre as a Director

Less than half of directors are independent

Rhinomed Limited Announces Retirement of Brent Scrimshaw, Non-Executive Director, Effective from November 17Th, 2023

Less than half of directors are independent

Rhinomed Limited, Annual General Meeting, Nov 17, 2023

Less than half of directors are independent

Full year 2023 earnings released: AU$0.039 loss per share (vs AU$0.02 loss in FY 2022)

New minor risk - Financial data availability

Less than half of directors are independent

New major risk - Market cap size

Less than half of directors are independent

Insider recently bought AU$242k worth of stock

Less than half of directors are independent

Less than half of directors are independent

Insider recently bought AU$372k worth of stock

Less than half of directors are independent

First half 2023 earnings released: AU$0.016 loss per share (vs AU$0.013 loss in 1H 2022)

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Rhinomed Limited, Annual General Meeting, Nov 18, 2022

Less than half of directors are independent

Rhinomed Limited Announces Rhinoswab Junior Study Confirms New Nasal Swab Is Most Accurate, Comfortable and Easy for Kids

Rhinomed Limited Appoints Lyn Swinburne AO as Non-Executive Director

Full year 2022 earnings released: AU$0.02 loss per share (vs AU$0.034 loss in FY 2021)

Rhinomed Limited Announces the Interim Results in the World First "Rhinoswab for Diagnosis of Respiratory Virus in Children" Trial

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Full year 2021 earnings released: AU$0.034 loss per share (vs AU$0.044 loss in FY 2020)

Non-Executive Director recently bought AU$77k worth of stock

Non-Executive Director recently bought AU$76k worth of stock

First half 2021 earnings released: AU$0.022 loss per share (vs AU$0.034 loss in 1H 2020)

Independent Non-Executive Chairman recently bought AU$180k worth of stock

Insider recently bought AU$435k worth of stock

Rhinomed Limited Detects SARS-CoV-2 in Doherty Inst. RT-PCR Study

Rhinomed Limited Announces Registration of Nasal Swab with Australian Therapeutic Goods Administration

Rhinomed Limited Announces Registration of Its Novel Nasal Swab with the US FDA

Insider recently bought AU$513k worth of stock

Insider recently bought AU$443k worth of stock

Insider recently bought AU$668k worth of stock

Insider recently bought AU$600k worth of stock

Rhinomed Limited Auditor Raises 'Going Concern' Doubt

Full year earnings released - AU$0.044 loss per share

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Membres du conseil d'administration

Durée moyenne de l'emploi